These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1242 related items for PubMed ID: 9867150

  • 1. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 4. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [Abstract] [Full Text] [Related]

  • 5. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.
    Cancer Biother Radiopharm; 2006 Apr 01; 21(2):88-100. PubMed ID: 16706629
    [Abstract] [Full Text] [Related]

  • 6. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 7. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
    Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA.
    Clin Cancer Res; 2004 Aug 01; 10(15):5014-21. PubMed ID: 15297402
    [Abstract] [Full Text] [Related]

  • 8. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

  • 9. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.
    Cancer Biother Radiopharm; 2001 Oct 15; 16(5):371-9. PubMed ID: 11776754
    [Abstract] [Full Text] [Related]

  • 10. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
    Wong JY, Somlo G, Odom-Maryon T, Williams LE, Liu A, Yamauchi D, Wu AM, Yazaki P, Wilczynski S, Shively JE, Forman S, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
    [Abstract] [Full Text] [Related]

  • 11. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy.
    Clarke KG, Odom-Maryon TL, Williams LE, Liu A, Lopatin G, Chou J, Farino GM, Raubitschek AA, Wong JY.
    Med Phys; 1999 May 15; 26(5):799-809. PubMed ID: 10360545
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
    Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA.
    J Nucl Med; 1997 Dec 15; 38(12):1959-66. PubMed ID: 9430477
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
    Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
    [Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 01; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 15. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N, Oriuchi N, Endo K, Inoue T, Kuroki M, Matsuoka Y, Tanada S, Murata H, Kim EE, Sasaki Y.
    J Nucl Med; 2000 Feb 01; 41(2):337-44. PubMed ID: 10688120
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Jun 01; 38(6):858-70. PubMed ID: 9189130
    [Abstract] [Full Text] [Related]

  • 17. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
    Pai-Scherf LH, Carrasquillo JA, Paik C, Gansow O, Whatley M, Pearson D, Webber K, Hamilton M, Allegra C, Brechbiel M, Willingham MC, Pastan I.
    Clin Cancer Res; 2000 May 01; 6(5):1720-30. PubMed ID: 10815890
    [Abstract] [Full Text] [Related]

  • 18. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.
    J Nucl Med; 2008 Jul 01; 49(7):1066-74. PubMed ID: 18552139
    [Abstract] [Full Text] [Related]

  • 19. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N, Saga T, Sakahara H, Yao Z, Nakamoto Y, Zhang M, Kuroki M, Matsuoka Y, Iida Y, Konishi J.
    J Nucl Med; 1999 Apr 01; 40(4):685-92. PubMed ID: 10210230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.